Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Pars-plana vitrectomy (PPV) is the cornerstone of surgical treatment for eyes with complicated proliferative diabetic retinopathy. Anti-VEGF intravitreal injection before PPV has shown a good effect on surgical outcomes. However, many patients present with co-morbidities that contraindicate the usage of anti-VEGF in the pre-operative period. Thus, cryoapplication, an old therapeutic tool for proliferative diabetic retinopathy may be a good alternative. We present herein a comparative study between peripheral retinal cryoapplication and anti-VEGF before vitrectomy for complicated proliferative diabetic retinopathy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Khairallah Moncef
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Type 1 or 2 diabetes mellitus

• Vitreous or retro-hyaloidal hemorrhage and/or tractional retinal detachment threatening or involving the macula

• No or less than 1000 impacts of preoperative retinal photocoagulation and/or iris rubeosis

• Only one eye per participant

Exclusion Criteria:

• Negative light perception

• Previous vitrectomy

• Contraindication to anti-VEGF therapy or retinal cryoapplication

• Associated rhegmatogenous retinal detachment